G. Richard Granneman

6.5k total citations · 2 hit papers
95 papers, 4.9k citations indexed

About

G. Richard Granneman is a scholar working on Pharmacology, Pediatrics, Perinatology and Child Health and Oncology. According to data from OpenAlex, G. Richard Granneman has authored 95 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Pharmacology, 29 papers in Pediatrics, Perinatology and Child Health and 22 papers in Oncology. Recurrent topics in G. Richard Granneman's work include Antibiotics Pharmacokinetics and Efficacy (31 papers), Drug Transport and Resistance Mechanisms (22 papers) and Pharmacogenetics and Drug Metabolism (20 papers). G. Richard Granneman is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (31 papers), Drug Transport and Resistance Mechanisms (22 papers) and Pharmacogenetics and Drug Metabolism (20 papers). G. Richard Granneman collaborates with scholars based in United States, United Kingdom and Germany. G. Richard Granneman's co-authors include Richard Bertz, Ann Hsu, John M. Leonard, Ellis V. Brown, John H. Cavanaugh, Dale J. Kempf, Eugene Sun, Akhteruzzaman Molla, Lawrence T. Sennello and Daniel W. Norbeck and has published in prestigious journals such as Journal of the American Chemical Society, Nature Medicine and Neurology.

In The Last Decade

G. Richard Granneman

94 papers receiving 4.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions

1997 605 citations Richard Bertz, G. Richard Granneman Clinical Pharmacokinetics profile →
Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

1996 601 citations Akhteruzzaman Molla, Marina Korneyeva et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
G. Richard Granneman United States	32	1.9k	1.3k	989	894	749	95	4.9k
Jérôme Biollaz Switzerland	41	1.8k 0.9×	1.2k 0.9×	432 0.4×	683 0.8×	643 0.9×	155	6.1k
Richard C. Brundage United States	38	1.5k 0.8×	814 0.6×	315 0.3×	1.1k 1.2×	744 1.0×	136	3.8k
Richard Bertz United States	29	1.9k 1.0×	895 0.7×	774 0.8×	602 0.7×	485 0.6×	113	3.6k
Francesca Aweeka United States	40	2.7k 1.4×	1.6k 1.2×	470 0.5×	800 0.9×	438 0.6×	143	5.4k
Eleni Aklillu Sweden	42	1.8k 0.9×	498 0.4×	2.5k 2.6×	949 1.1×	1.2k 1.6×	174	6.3k
Chantal Csajka Switzerland	36	1.1k 0.6×	522 0.4×	460 0.5×	596 0.7×	704 0.9×	165	4.4k
Elisabeth Rey France	41	1.0k 0.5×	445 0.3×	486 0.5×	2.3k 2.5×	601 0.8×	142	4.9k
Laurent A. Décosterd Switzerland	50	3.8k 2.0×	2.2k 1.7×	768 0.8×	1.2k 1.4×	1.6k 2.2×	270	10.1k
Catia Marzolini Switzerland	36	3.5k 1.8×	1.9k 1.5×	712 0.7×	1.3k 1.5×	1.4k 1.9×	130	6.0k
Rory P. Remmel United States	45	791 0.4×	377 0.3×	965 1.0×	1.4k 1.6×	894 1.2×	148	5.5k

Countries citing papers authored by G. Richard Granneman

Since Specialization

Citations

This map shows the geographic impact of G. Richard Granneman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Richard Granneman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Richard Granneman more than expected).

Fields of papers citing papers by G. Richard Granneman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Richard Granneman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Richard Granneman. The network helps show where G. Richard Granneman may publish in the future.

Co-authorship network of co-authors of G. Richard Granneman

This figure shows the co-authorship network connecting the top 25 collaborators of G. Richard Granneman. A scholar is included among the top collaborators of G. Richard Granneman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Richard Granneman. G. Richard Granneman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bertz, Richard, et al.. (2000). Assessment of the pharmacokinetic interaction between ABT-378/ritonavir and efavirenz in healthy volunteers and in HIV + subjects. 40. 14. 1 indexed citations

Kumar, Gondi, Ellen Roberts, Dean Hickman, et al.. (1999). Potent Inhibition of the Cytochrome P-450 3A-Mediated Human Liver Microsomal Metabolism of a Novel HIV Protease Inhibitor by Ritonavir: A Positive Drug-Drug Interaction. Drug Metabolism and Disposition. 27(8). 902–908. 133 indexed citations

Wong, Shekman & G. Richard Granneman. (1998). Modeling of sertindole pharmacokinetic disposition in healthy volunteers in short term dose-escalation studies. Journal of Pharmaceutical Sciences. 87(12). 1629–1631. 14 indexed citations

Gustavson, Linda E., et al.. (1998). Lack of a Clinically Significant Pharmacokinetic Drug Interaction Between Tiagabine and Valproate. American Journal of Therapeutics. 5(2). 73–80. 16 indexed citations

Hsu, Ann, G. Richard Granneman, Guoliang Cao, et al.. (1998). Pharmacokinetic Interaction between Ritonavir and Indinavir in Healthy Volunteers. Antimicrobial Agents and Chemotherapy. 42(11). 2784–2791. 130 indexed citations

Wong, Shekman, et al.. (1997). The Effect of Erythromycin on the CYP3A Component of Sertindole Clearance in Healthy Volunteers. The Journal of Clinical Pharmacology. 37(11). 1056–1061. 12 indexed citations

Bertz, Richard & G. Richard Granneman. (1997). Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions. Clinical Pharmacokinetics. 32(3). 210–258. 605 indexed citations breakdown →

Samara, Emil, et al.. (1997). Population analysis of the pharmacokinetics and pharmacodynamics of seratrodast in patients with mild to moderate asthma*. Clinical Pharmacology & Therapeutics. 62(4). 426–435. 15 indexed citations

Molla, Akhteruzzaman, Marina Korneyeva, Qing Gao, et al.. (1996). Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Medicine. 2(7). 760–766. 601 indexed citations breakdown →

10.

Samara, Emil, et al.. (1996). Assessment of the Pharmacokinetic ‐Pharmacodynamic Interaction Between Terazosin and Finasteride. The Journal of Clinical Pharmacology. 36(12). 1169–1178. 5 indexed citations

11.

Granneman, G. Richard, Rene A. Braeckman, Charles Locke, et al.. (1995). Effect of Zileuton on Theophylline Pharmacokinetics. Clinical Pharmacokinetics. 29(Supplement 2). 77–83. 31 indexed citations

12.

Awni, Walid M., Ziad Hussein, John H. Cavanaugh, G. Richard Granneman, & Louise M. Dubé. (1995). Assessment of the Pharmacokinetic Interaction between Zileuton and Digoxin in Humans. Clinical Pharmacokinetics. 29(Supplement 2). 92–97. 5 indexed citations

13.

Granneman, G. Richard, Rene A. Braeckman, & Keith Erdman. (1995). Determination of a New 5-Lipoxygenase Inhibitor, Zileuton, and its Inactive N-Dehydroxylated Metabolite in Plasma by High Performance Liquid Chromatography. Clinical Pharmacokinetics. 29(Supplement 2). 1–8. 24 indexed citations

14.

Awni, Walid M., Rene A. Braeckman, G. Richard Granneman, Galen Witt, & Louise M. Dubé. (1995). Pharmacokinetics and Pharmacodynamics of Zileuton after Oral Administration of Single and Multiple Dose Regimens of Zileuton 600mg in Healthy Volunteers. Clinical Pharmacokinetics. 29(Supplement 2). 22–33. 30 indexed citations

15.

Awni, Walid M., John H. Cavanaugh, Galen Witt, G. Richard Granneman, & Louise M. Dubé. (1995). The Effect of Food on the Pharmacokinetics of Zileuton. Clinical Pharmacokinetics. 29(Supplement 2). 62–66. 8 indexed citations

16.

Hussein, Ziad, et al.. (1994). Characterization of the pharmacokinetics and pharmacodynamics of a new oral thromboxane A2-receptor antagonist AA-2414 in normal subjects: Population analysis. Clinical Pharmacology & Therapeutics. 55(4). 441–450. 7 indexed citations

17.

Hussein, Ziad, Sou-Yie Chu, & G. Richard Granneman. (1993). Enantioselective determination of DN-2327, a novel non-benzodiazepine anxiolytic, and/or its active metabolite in human plasma and urine using high-performance liquid chromatography. Journal of Chromatography B Biomedical Sciences and Applications. 613(1). 113–120. 6 indexed citations

18.

Hussein, Ziad, G. Richard Granneman, Emil Samara, et al.. (1993). Age‐related differences in the pharmacokinetics and pharmacodynamics of lansoprazole. British Journal of Clinical Pharmacology. 36(5). 391–398. 39 indexed citations

19.

Granneman, G. Richard, et al.. (1992). The Effect of Food on the Bioavailability of Temafloxacin. Clinical Pharmacokinetics. 22(Supplement 1). 48–56. 9 indexed citations

20.

Granneman, G. Richard, G. Mahr, C. Locke, et al.. (1992). Pharmacokinetics of Temafloxacin in Patients with Liver Impairment†. Clinical Pharmacokinetics. 22(Supplement 1). 24–32. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact